Most retinoic acid (RA) in the embryonic mouse is generated by three retinaldehyde dehydrogenases (RALDHs). RALDH1 (also called E1, AHD2 or ALDH1) is expressed in the dorsal retina, and RALDH2 (V2, ALDH11) generates most RA in the embryonic trunk. The third one, RALDH3 (V1), synthesizes the bulk of RA in the head of the early embryo. We show here that RALDH3 is a mouse homologue to ALDH6, an aldehyde dehydrogenase cloned from adult human salivary gland (Hsu, L.C., Chang, W.-C., Hiraoka, L., Hsien, C.-L., 1994. Molecular cloning, genomic organization, and chromosomal localization of an additional human aldehyde dehydrogenase gene, ALDH6. Genomics 24, 333±341), which was recently reported to act as a RALDH (Yoshida, A., Rzhetsky, A., Hsu, L.C., Chang, C., 1998. Human aldehyde dehydrogenase gene family. Eur. J. Biochem. 251, 549±557). RALDH3 expression begins in the surface ectoderm over the optic recess. In rapidly changing expression patterns it labels the appearance of several ectodermal structures: it marks the formation of the lens and the olfactory organ from ectodermal placodes, and it delineates the beginning eyelid ®eld. Within the optic vesicle, RALDH3 is expressed in the ventral retina and the dorsal pigment epithelium. In the telencephalon, RALDH3 is expressed at high levels in the lateral part of the ganglionic eminence. From here it extends via the piriform cortex into the lower part of the septum. Of the three RALDHs, RALDH3 shows the strongest predilection for epithelia. q
Results
For an estimate of the relative magnitudes of RA synthesis at different sites in the embryonic head (Fig. 1a) , we cultured similar amounts of dissected tissue samples and compared the RA levels released into the supernatants with RA reporter cells (McCaffery et al., 1992; . The highest RA synthesis was by the retinas. In the brain, the isolated meninges were high, consistent with high expression of RALDH2 at this site (Yamamoto et al., 1996; Niederreither et al., 1997) . Most of the brain samples, including the hippocampus, cerebellum, medial ganglionic eminence and superior colliculus, showed baseline levels. Only the lateral ganglionic eminence synthesized signi®cant RA amounts. For the identi®cation of the enzyme activity , we compared samples of medial and lateral ganglionic eminence by analyzing consecutive protein fractions from isoelectric focusing gels with RA reporter cells for capacity to oxidize retinaldehyde to RA (Fig. 1b) . The lateral ganglionic eminence sample contains a single retinaldehyde dehydrogenase peak that focuses at pI 5.7, which is the same charge as the V1 activity, the RALDH in ventral retina .
To characterize the RALDH mRNA in the ganglionic eminence, we followed the same strategy as used for RALDH2 (Zhao et al., 1993 (Zhao et al., , 1996 : we ampli®ed all aldehyde dehydrogenases by PCR with degenerate primers to two highly conserved sequence stretches, and tested representatives of each enzyme for differential expression patterns. The most abundant clone (#80) showed the distribution we were searching for: it is high in ventral retina and lateral ganglionic eminence and low or absent from the dorsal retina and medial ganglionic eminence (Fig. 1c) . . Similar explant assays, in which the same or different cranial CNS regions were sampled at various embryonic ages, all identi®ed the same three main RA sources (data not shown). hipp, hippocampus; cer, cerebellum; men, meninges; LGE, lateral ganglionic eminence; MGE, medial ganglionic eminence; ret, retina; sc, superior colliculus. (b) Zymography bioassay for detection of RA generating enzyme activity in small tissue samples dissected from the ganglionic eminence and separated by isoelectric focusing (IEF). The amounts of RA synthesized in the fractions, sampled consecutively along the gel, are indicated as arbitrary colorimetric readings for b-galactosidase product taken from an ELISA reader . Note that the LGE shows a single enzyme peak. This peak co-migrates with the V1 enzyme activity detected in ventral embryonic retina (McCaffery and Dra Èger, 1994) . (c) Northern blots showing the distribution of the aldehyde dehydrogenase #80 in different embryonic tissues. Similar to the ALDH6 mRNA (Hsu et al., 1994) , the size of the #80 mRNA (3.4 kb) is signi®cantly larger than the mRNA of most other aldehyde dehydrogenases. The distribution of #80 is identical to the distribution of the V1 activity previously localized by biochemical assays on dissected tissue samples Dra Èger, 1994, 1995) . (d) Deduced protein sequence of the RALDH3 enzyme lined up with human ALDH6 (Hsu et al., 1994) , mouse RALDH2 (Zhao et al., 1996) and mouse RALDH1 (Rongnoparut and Weaver, 1991) . Amino acids that are identical to RALDH3 in all sequences are indicated by dashes, and alignment gaps are indicated by dots.
None of the other clones were asymmetrically expressed in retina or ganglionic eminence. Comparisons of different embryonic tissues show high expression of clone #80 only in the eyes, nose and ganglionic eminence, and no detectable signal in any of the other tested samples (Fig. 1c) . The deduced amino acid sequence (Fig. 1d ) has 93.9% identity to ALDH6, a class-1 aldehyde dehydrogenase cloned from adult human salivary gland (Hsu et al., 1994) . ALDH6 was recently reported to act as retinaldehyde dehydrogenase (Yoshida et al., 1998) . Because of this activity, we call it here RALDH3 (GenBank accession number for RALDH3: BankIt330316 AF253409). In Fig. 1d , the RALDH3 sequence is also compared to the other two RA-generating dehydrogenases in the mouse, RALDH1 and RALDH2 (Rongnoparut and Weaver, 1991; Zhao et al., 1996) . RALDH3 is 70.7% homologous to RALDH2 and 67.8% homologous to RALDH1.
To analyze RALDH3 expression in the embryo, we performed in situ analyses on whole-mount preparations (Fig. 2) . Consistent with biochemical assays on the V1 activity , RALDH3 mRNA becomes ®rst detectable in the rostral head during the eighth day of development, slightly before embryonic day 8.5 (,E8.5), and the labeling rapidly grows very intense (Fig . Fig. 2 . Whole-mount in situ preparations for RALDH3 mRNA from embryonic day 8 (E8.0) to postnatal day 0.5 (P0.5). The preparations are all shown at the same scale: whole embryos in (a±c), half-heads in (d,e), and retina cups in (f). Note that most of RALDH3 detectable here is in the eye/olfactory region and adjoining face, and that its location shifts rapidly. In addition to the face, two other locations of RALDH3 expression can be seen: streaks along the spinal cord (a) and labeling in the otic vesicle (d). opt rec, optic recess; olf pit, olfactory pit; otic ves, otic vesicle; D, dorsal; V, ventral. Scale: 500 mm. Fig. 3 . Whole-mount in situ preparations to compare the RALDH3-labeled region with the eye marked by the transcription factors Rx and Pax6 (Walther and Gruss, 1991; Furukawa et al., 1997; Mathers et al., 1997) . The embryos are around E9 in age. Scale: 250 mm. 2a). Around E9, the heavy labeling occludes the entire eye region and extends signi®cantly beyond it. This large size is apparent in the line-up of a RALDH3-labeled embryo ( Fig.  3 ) with similar-aged embryos reacted by in situ hybridization for the transcription factors Rx and Pax6, which serve here as markers for the location of the eye (Walther and Gruss, 1991; Furukawa et al., 1997; Mathers et al., 1997) .
RALDH3 labeling covers an area about three times the size of the eye. Over the following 3 days, the RALDH3 labeling patterns change rapidly and in an identical manner in all embryos (Fig. 2a±e) .
For a detailed localization of the changing RALDH3 signal, we compared the whole-mount preparations ( Fig.  2) with coronal sections through the heads (Fig. 4) . Fig. 4 . Coronal sections through heads and eyes at different ages labeled for RALDH3 mRNA. Because the E11 preparation is from an albino and the E12 from a pigmented embryo, the RPE labeling is only obvious in the E11 preparation (e), but is partially occluded by melanin at E12 (f). The section in (f) runs along the ventral groove of the optic stalk, the optic ®ssure, which extends from the eye towards the diencephalon. The unlabeled material in this groove represents blood vessels and early optic axons. forebrain pl, forebrain plate; opt rec, optic recess; dienceph, diencephalon; opt ves, optic vesicle; le pl, lens placode; D RPE, dorsal retinal pigment epithelium; V ret, ventral retina; olf pit, olfactory pit; opt stalk, optic stalk. Scales: (a,b,e,f) 100 mm; (c,d) 250 mm. RALDH3 expression starts in the epidermis covering the posterior part of the optic recess and extending behind it (Figs. 2a and 4a) . A few hours later at E8.8, RALDH3 labeling has expanded and grown very intense (Figs. 2a  and 4b ). It is still entirely restricted to the surface ectoderm, which is now labeled over a triangular-shaped area. Early on E9, RALDH3 begins to appear in the neural ectoderm of the eye vesicle (see below). The strongest expression for the next day, however, continues to be in the skin. It is highest in two thickening ectodermal regions of the face, the lens and olfactory placodes. By E10, the labeled surface area is still contiguous, but it starts to constrict down to the two placodes (Figs. 2c and 4c,d ). Over the next half day, all RALDH3 mRNA is very rapidly eliminated from most of Fig. 6 . Spatio-temporal comparisons of the four enzymes that regulate RA levels in the eye: RALDH1, RALDH2, RALDH3 and CYP26. (a) Two young embryos from their ventral sides; (b±d) coronal sections; (e±g) half-head preparations; (h±j) isolated retina cups. All preparations shown here represent in situ hybridizations, except for (d), in which RALDH1 is labeled with an antiserum. RALDH2, which is transiently expressed at the ventral eye anlage during the ®rst part of E8, is absent from the neural retina later on. The expressions of the three remaining enzymes overlap partially in the eye vesicle, but then shift rapidly into separate territories. They divide the neural retina into three RA concentration zones: RALDH1 forms moderately high RA levels in the dorsal retina, CYP26 generates a RA-poor horizontal border, and RALDH3 accounts for the very high RA levels in ventral retina. In addition to the developing eye and olfactory organ, the whole-mount preparations indicate weakly that the otic vesicle is labeled by the RALDH3 probe (Figs. 2d and 6e) . Indeed, all three retinaldehyde dehydrogenases are expressed in the developing ear in patterns that seem to delineate a cross-hair coordinate system; this feature was not examined here. opt pit, optic pit; V trunk, ventral trunk; naso-lac, naso-lacrimal groove; an asterix marks the everted di/mesencephalic wall, an artifact of the half-head preparations; opt ®ss, optic ventral ®ssure, marked here by white arrow heads; black arrows indicate locations of optic disc in the retina cups. Scales: (a) 50 mm; (b±d) 200 mm; (e±g) 1 mm; (h±j) 50 mm. the surface epithelium, except for the lens bud and olfactory pit (Fig. 2d) . In whole-mounts, all eyes seem to have a central hole at this age. In sections, this hole is seen to be formed by the approaching margins of the lens bud (Fig. 4e) . As soon as the lens has closed, it loses RALDH3 mRNA (Figs. 2e and 4f) . Similarly, as the olfactory pit develops into the olfactory organ, all RALDH3 mRNA disappears rapidly from the external surface of the nose (Fig. 2e) , but sections reveal that heavy expression continues in the internal epithelium of the olfactory organ.
Early on E11 and brie¯y after all RALDH3 labeling has been cleared from the epidermis, strong surface labeling reappears in the eye region, but now in a very different shape (Fig. 2e) . It forms a rectangle covering the eye obliquely, with a row of labeled cells extending into the nasolacrimal groove (white arrow, Fig. 2e ). This pattern delineates the future eye lid system, that is, mainly the epidermal± conjunctival transition and the naso-lacrimal duct. The dorso-ventral axis of the rectangle deviates by ,358 from the dorso-ventral eye axis, which is the orientation of the lid ®ssure relative to the eye by the time the lids close at E15.5.
Compared to the highly dynamic mode of RALDH3 expression in the surface epithelium, the expression in the neural epithelium changes more slowly. Early on E9, when the eye vesicle begins to¯atten, ®rst the dorsal part of the future retinal pigment epithelium (RPE) becomes RALDH3-positive and then the beginning ventral retina (Fig. 4c) . Labeling of the dorsal RPE continues for a few days, and then fades away. As the neural retina thickens, it becomes the dominant location of RALDH3 expression by far. The RALDH3 mRNA covers the ventral two-thirds of the retina up to a horizontal border above the optic disc (Fig.  4f) . Within this region, RALDH3 forms a ventro-dorsal gradient that becomes more pronounced as the retina grows. At no point is RALDH3 expressed in the dorsal retinal periphery, but all dorsal eye labeling apparent in whole-mounts (Fig. 2e) re¯ects RPE labeling. Later during E11, just before the ®rst optic axons begin to grow out, the epithelium of the optic stalk becomes transiently RALDH3-positive. Whole-mounts of isolated retina cups at later ages (Fig. 2f) show strong RALDH3 labeling in the ventral part throughout embryonic development. Postnatally the retina signal slowly disappears.
The RALDH3 signal in the telencephalon becomes detectable a few days after the eye labeling, early during E11. It begins as a rim of small labeled pro®les located at the external margin of the ventro-lateral telencephalic wall in a location that seems to be relatively close to the RALDH3 surface expression. This sequence of RALDH3 expression is likely to be related to a phenomenon described by LaMantia et al. (1993) : they propose that inductive RA interactions link the olfactory placode with the telencephalon. Over the following day, the RALDH3 signal intensi®es, and the labeled pro®les shift gradually to a deeper position within the lateral ganglionic eminence and ventral cortex (Fig. 5a) . The RALDH3 signal is strongest in the rostral part of the lateral ganglionic eminence. At this level, it consists of a streak of heavily labeled cells extending from the piriform cortex with a long arm deep into the lateral ganglionic eminence and a short arm into the septum (Fig. 5b,c) . No RALDH3 labeling is ever visible in the medial ganglionic eminence. The intensity of the RALDH3 signal fades in the older embryo, and only very weak labeling is detectable in the newborn. The overall location remains similar, except that the labeled pro®les move deeper towards the subventricular zone. The in situ labeling does not give any hints to the nature of the RALDH3-positive pro®les. They do not seem to signi®cantly migrate tangentially like neurons, or reveal any radial processes like radial glia. They could, however, represent the perikaryal regions of a subtype of radial glia, or give rise to radial glia, as Toresson et al. (1999) reported that RA synthesis in passaged cultures of lateral ganglionic eminence co-segregates with radial glia cells.
To view the changing RA patterns in the developing eye, we compared the RALDH3 expression to the other three retinoid-metabolizing enzymes that modulate RA levels ( Fig. 6 ): the RA-synthesizing dehydrogenases RALDH1 and RALDH2, and the RA-degrading oxidase CYP26 (White et al., 1996; Fujii et al., 1997; Ray et al., 1997; McCaffery et al., 1999) . RALDH2 is the ®rst of the four enzymes expressed in the eye region. Early on E8 it appears transiently at the ventral edge of the eye ®eld (Fig. 6a) , and over the next half day it disappears; it is never expressed in the neural retina Wagner et al., 2000) . About 8 h after RALDH2, RALDH3 expression begins in the ectoderm. Brie¯y thereafter, the mRNA of the RA degrading CYP26 becomes detectable at the dorsal tip of the eye vesicle, and then the RALDH1 dehydrogenase in the dorsal neural retina (Fig. 6b±d) (McCaffery et al., 1999) . By E11.5, the expression of the three enzymes has shifted and segregated within the eye, as shown in the whole-mounted half-heads (Fig. 6e±g) . The rectangular eyelid precursor ®eld, which is conspicuous in the RALDH3 view, is also weakly delineated by RALDH1. In the eye itself, a horizontal boundary formed by CYP26 separates a dorsal RALDH1/RALDH3 compartment from a ventral RALDH3 compartment. The division of the neural retina into three enzyme zones along the dorso-ventral axis is illustrated in isolated retina cups (Fig. 6h,i) . These preparations reveal a characteristic that is not visible in the less sensitive half-head preparations: the RALDH1 expression extends from the dorsal retina along the temporal margin (T) all the way down to the remnant of the optic ®ssure. The lower part of the temporal edge is thus the only site where RALDH1 and RALDH3 expression overlap in the embryonic retina.
Methods
Experiments were done on embryos raised in a B6/D2 outbred colony and staged following the criteria of Theiler
